Screening and identifying molecules target to checkpoint pathways has fostered the development of checkpoint-based anticancer strategies. Among these targets, inhibition of chk2 may induce cell death for tumors whose growth depends on enhanced chk2 activity. However, improvement of the potency and specificity of such therapeutics remains a major challenge. To resolve this problem, we constructed M3, a novel recombinant adenovirus with a 27-bp deletion in E1A CR2 region by which to realize tumorspecific replication, and an 829-bp of antisense chk2 fragment inserted into the E3 coding region. In this design, M3 exploited the native adenovirus E3 promoters to express antisense chk2 cDNA in a viral replication-dependent fashion, and preferentially silenced the chk2 gene in tumor cells. In vitro and in vivo assays confirmed that downregulated chk2 expression induced by M3 infection was tumor-specific and virus replication-dependent. Furthermore, systemic administration of M3 combined with a low dose of cisplatin cured 75% (9/12) of orthotopic hepatic carcinoma mouse models that were otherwise resistant to cisplatin. Our results indicated that the upcoming development in this field would improve the antitumor efficacy and maximize the synergistic effect of oncolytic viruses administered with traditional chemotherapy or radiotherapy.
Introduction
Gene therapy is being actively explored as potential treatment for a number of human malignancies. 1 Development of viral agents with tumor selectivity, named oncolytic viruses, has been considered as one of the central goals in the field. 2 Among these, oncolytic adenovirus has a number of attractive features both as a treatment modality and a vector for gene delivery. 3, 4 The most studied oncolytic adenovirus so far named onyx-015 5 (also known as dl1520 or CI-1042) is an adenovirus with the E1B 55 kDa gene deleted. In clinical trials, onyx-015 has shown encouraging outcome in patients with recurrent head and neck cancer when in combination with chemotherapy. 6 However, onyx-015 per se has demonstrated only limited antitumoral efficacy, as the deletion of E1B 55 kDa conferring tumor selectivity also reduces the potency of the viral replication in tumors. 7 The E1A-CR2 mutant dl922-947 replicated effectively in a wide range of tumor cells, whereas replication was reduced by several logs in quiescent normal cells. 8 The dl922-947 demonstrated much more superior potency to onyx-015 both in vitro and in vivo. 8, 9 Two encouraging strategies are being explored to improve the potential utility of this kind of oncolytic treatment. First, because replication-selective viral treatment should not lead to cross-resistance with standard therapies, combinations with radiotherapy and chemotherapy might lead to additive or synergistic efficacy. 6, [10] [11] [12] [13] Second, viruses can be 'armed' to express exogenous therapeutic genes including cytokines or prodrug-activating enzyme, which may enhance tumor eradication through multiple avenues of attack. [14] [15] [16] Thus, in this study, we were intended to combine both strategies together.
A number of surveillance systems, defined as DNA damage-induced checkpoints, exist to block cell cycle progression in response to DNA damage agents such as chemo-or radiotherapy. 17 Such checkpoints provide tumor cells time to repair before cell cycle progression is recovered, and promote cell survival upon genotoxic challenge. Correspondingly, initiation and execution of checkpoints may reduce the efficiency of anticancer therapy. 18 For this reason, substantial effort has gone into exploiting specific molecules to modulate checkpoints for therapeutic intervention. 19, 20 Checkpoint kinase 1 (chk1) and chk2 are serine/threonine protein kinases that play essential roles in S and G2/M checkpoint pathways. 18, 21 Whereas chk1 acted as a 'workhorse' in cellular response to DNA damage or stalled replication, chk2 acted as an 'amplifier' in these procedures. 22 In this study, we constructed and characterized M3, a novel E1A CR2-deleted Adv5 with a fragment of antisense chk2 cDNA inserted into the deleted 6.7K/ gp19K region. M3 preferentially replicated in a wide range of tumor cells and silenced cancer-associated chk2. By combing oncolysis with chk2 targeting, M3 demonstrated potent antitumor efficacy superior to its parent oncolytic virus, Adv5/dE1A, in cell line and animal studies. Remarkably, systemic administration of M3 followed by cisplatin reduced complete response in most orthotopic HepG2 hepatic carcinoma model mice that were otherwise resistant to cisplatin and disseminated metastases.
Materials and methods

Viruses and cells
Adv5/dE1A is an adenovirus mutant with a 27-bp deletion from wt-Adv5 bases 920-946 corresponding to the amino-acid sequence of the E1A protein conserved region-2 (CR2) necessary for pRb binding. Adv5/dE1A was constructed in our laboratory according to the protocol described elsewhere. 23 M3 was driven from Adv5/dE1A through replacement of the 6.7K/gp19K open reading frame in the E3 region, corresponding to wt-Adv5 bases 28 530-29 360, by a fragment of reverse chk2 cDNA (bases 1686-858) with a newly introduced ClaI restriction site at each end. The virus mutant was constructed using ligation method by homologous recombination in 293 cells (American Type Culture Collection, ATCC, Rockville, MD) as described previously. 24 The replication-defective recombinant adenovirus Adv-TK, containing a herpes simplex virus-thymidine kinase (HSV-TK) gene under control of a Rous sarcoma virus long terminal repeat (RSV-LTR) promoter in the region of the excised E1 adenoviral genes, has an intact E3 region and was used as a vehicle control. Wt-Adv5 was obtained from ATCC. To prepare high-titer viral stocks, wt-Adv5 or adenovirus mutants were propagated in 293 cells and purified by CsCl banding. Viral stocks were titered on 293 cells according to the TCID 50 method following the instructions in the AdEasy application manual (Quantum Biotechnologies, Montreal, Quebec, Canada) and are presented as plaque forming units (PFU). The following tumor cell lines varying in p53 and Rb status and tissue of origins were obtained from the ATCC: breast carcinoma (MCF-7, p53 and Rb wt), cervical carcinoma (HeLa, p53 inactivated by HPV E6 and mutant Rb), lung carcinoma (A549, p53 wt and Rb mutant), hepatocellular carcinoma (HepG2, p53 wt and Rb mutant) and breast carcinoma (MDA-MB-231, p53 mutant and Rb wt). Ovarian carcinoma cell line A2780 with wt-p53 and mutant Rb was obtained from the China Center for Type Culture Collection (CCTCC, Wuhan, China). Cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Lung-derived primary human microvascular endothelial cells (MEVC) and human normal hepatocytes (h NHeps) were purchased from Cambrex Bio Science Rockland Inc. (Rockland, ME) and cultured according to the manufacturer's instructions and our previous description. 25 Verification of M3 by ClaI digestion Seventy percent confluent 293 cells were infected with M3 at an MOI of 10. After 3 days of culture, 293 cells were collected for isolation of viral genome DNA. Virus DNA (2 mg) was digested with ClaI and checked for restriction polymorphism by running the cleaved DNA on a 0.8% agarose gel.
Detection of fusion mRNA containing antisense chk2 and ADP cDNA A549 cells were infected with Adv-TK, M3 or wt-Adv5 at an MOI of 5 and switched to complete culture medium for another 24 h culture. The cells were collected for extraction of total RNA. A 2 mg portion of total RNA treated with DNase I (Gibco, Grand Island, NY) was used for reverse transcriptase reaction. A total of 5 ml of reverse transcriptase mixture was amplified using PCR. For amplification of fusion transcripts containing sequences of antisense chk2 cDNA and sense ADP cDNA, 5 0 -end sense primer from antisense chk2 cDNA (5 0 -ACC CAC TTC CCT GAA AAT CC-3 0 ) and 3 0 -end antisense primer complimentary to the coding region of ADP gene (5 0 -CCA CCA CAT GCC CAA GTT AT-3 0 ) were used. PCR conditions were as follows: denaturing at 951C for 30 s, annealing at 551C for 40 s and extension at 721C for 40 s for 30 cycles. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was chosen as an endogenous marker to check the integrity of mRNA. A 5 0 -end sense primer (5 0 -ACG GAT TTG GTC GTA TTG GG-3 0 ) and a 3 0 -end antisense primer (5 0 -TGA TTT TGG AGG GAT GTC GC-3 0 ) were used to amplify a 230-bp-long fragment in GAPDH mRNA.
Detection of ADP mRNA expression A549 cells were infected with M3 or Adv/dE1A at an MOI of 5 and switched to complete culture medium, and then cells were collected for ADP mRNA expression by RT-PCR as described above. The primers for ADP detection were as follows: sense 5 0 -CCT GAC CGT AAA CCA GAC-3 0 and antisense 5 0 -CTA TGG AGA ACC ACC ACA-3 0 . PCR conditions were as follows: denaturing at 951C for 30 s, annealing at 571C for 40 s and extension at 721C for 40 s for 30 cycles. GAPDH was used to normalize the ratios of relative expression.
Real-time RT-PCR Cells were infected with Adv-TK, wt-Adv5 or M3 at an MOI of 5. After 24 h culture, total RNA was extracted and 2 mg RNA was treated with DNase I before singlestrand cDNA synthesis. Reverse transcription reaction mixture (1 mg) was added to 10 Â buffer 2. 0 -TGA CTG CTA TAA CTC GAT GA-3 0 ) for GAPDH gene were used. The reaction conditions were as follows: initial denaturation at 951C for 3 min followed by 35 cycles of denaturation at 941C for 30 s, annealing at 561C for 40 s and extension at 721C for 40 s. Following the PCR reaction, a melting curve assay was performed to determine the purity of the amplified product. Threshold cycle value (C T ) is given for each sample, and indicates the cycle at which a statistically significant increase in fluorescence was first detected. These values were then normalized by the average expression of a housekeeping gene (GAPDH) to determine ratios of relative expression.
Viral production assays and in vitro cytopathic effects The viral production was quantified to evaluate the relative replication efficacy of M3 versus Adv-TK or wt-Adv5 in tumor cells (A549, MDA-MB-231) and primary normal human MEVC. Both proliferative MEVC (P-MEVC, with activated checkpoint) and non-proliferative MEVC (Q-MEVC, with nonactivated checkpoint) were included in the experiment. The cells were grown to 70% confluence and infected with Adv-TK, M3 or wt-Adv5 for 90 min at an MOI of 5. For Q-MEVC, MEVC was grown to reach complete confluence and maintained in this state for 2 days followed by viral infection under identical experimental conditions. The cells were then switched to complete culture medium and maintained in a humidified atmosphere with 5% CO 2 at 371C. After 48 h incubation, the cells were subsequently scraped into culture supernatant and cell lysates were prepared by three cycles of freezing and thawing. Serial dilutions of the lysates were titered on 293 cells using the TCID 50 method according to the instructions in the AdEasy application manual (Quantum Biotechnologies, Montreal, Canada) and are presented as PFU. Results are the means of titers for quadruplicate samples. The in vitro CPE assays were aimed at assessing the killing potency of virus by replication-dependent lysis. CPE of virus mutants for a given individual cell type was assessed on the day on which complete CPE for wt-Adv5 was achieved at an MOI of 0.1. Seventy percent confluent cells were infected with Adv-TK, M3 or wt-Adv5 for 90 min at an MOI of 0.01-500, and then switched to complete culture medium for culture in a humidified atmosphere with 5% CO 2 at 371C. Culture medium was changed at 72-h intervals until the time of assay. For CPE experiments with non-proliferative Q-MEVC, MEVC were made proliferation-free following growth to complete confluence and maintained in this state for at least 2 days before initiation of infection. Once complete CPE for wt-Adv5 at an MOI of 0.1 was obtained for the particular cell type, the culture plates were stained with crystal violet solution and examined for CPE.
Quantitative cytotoxicity assay
The cytotoxicity assay was performed using the MTT method. Briefly, cells were plated in 96-well tissue culture plates with a cell density of 5 Â 10 4 /ml. The cells were grown to 70% confluence and infected with M3 for 90 min at an MOI of 0.1-1000, and then switched to complete culture medium for culture in a humidified atmosphere with 5% CO 2 at 371C for 72 h. For cytotoxicity experiments with Q-MEVC, MEVC were made proliferation-free following growth to complete confluence and maintained in this state for at least 2 days before initiation of infection. After incubation, the cells were stained with MTT reagent (5 mg/ml; Sigma, Germany). The optical density was measured at 570 nm and growth suppression rate was calculated using the following formula: growth suppression rate (%) ¼ (1ÀA 570 of experimental wells)/A 570 of mock control wells Â 100%.
Western blot
The total protein used for Western blotting was prepared using M-PERt mammalian protein extraction reagent (Pierce, Rockford, IL). Pretreated cells were pelleted by centrifugation at 2000 g for 10 min. M-PERt reagent was added to the cell pellet containing 1 Â protease inhibitor cocktail (Sigma Chemical Co.) and gently mixed for 10 min. Cell debris were removed by centrifugation at 27 000 g for 15 min. Protein concentration was determined using the Bradford assay (Bio-Rad, Hercules, CA). A 20 mg portion of total protein (40 mg for Q-MVEC) was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein was transferred to nitrocellulose membranes, which were blocked with phosphatebuffered saline (PBS) containing 5% non-fat milk for 1 h and then incubated with 1 mg/ml specific antibody at 41C overnight. After washing with TTBS (0.1 M Tris-HCl, pH 7.5; 0.9% sodium chloride; 0.05% Tween 20) for 4 Â 15 min, filters were incubated with 1:5000 horseradish peroxidase (HRP)-labeled second antibody for 1 h at room temperature and washed with TTBS for 4 Â 15 min. Immunodetection was performed using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). Second antibody and antibodies to chk2, chk1 and b-actin were purchased from Santa Cruz Biotechnology, Santa Cruz, CA.
Apoptosis assay
Tumor cells (MCF-7, A2780, HeLa) and MEVC (nonproliferative or proliferative) were infected with Adv5/ dE1A or M3 adenovirus mutants at an MOI of 1 and cultured for another 24 h. PBS was included as a mock control. Cells were then treated as follows: HeLa cells were exposed to irradiation at a dose of 10 Gy, MCF-7 cells and MEVC cells were exposed at a dose of 6 Gy and A2780 cells were treated with cisplatin at a dose of 20 mM. Cells were then maintained in complete medium for another 48 h with HeLa, 24 h with MCF-7, 24 h with A2780 or 24 h with MEVC. On the basis of studies using a wide range of experimental time points, we chose these time points at which DNA damage agents (cisplatin or irradiation) alone yield slight apoptotic response to test the sensitizing effects of Adv5/dE1A or M3. Pretreated cells were resuspended in binding buffer containing 10 mM Hepes, 140 mM NaCl and 2.5 mM CaCl 2 at a density of 1 Â 10 6 cells/ml. A 5 ml portion of FITC plus annexin V (BD Pharmingen, San Jose, CA) and 10 ml of PI solution at a concentration of 50 mg/ml in PBS were then added, and the cells were incubated for 20 min at room temperature in the dark. Stained cells were subsequently analyzed using a FACSort Flow Cytometer (Becton Dickinson, San Jose, CA). CELLQuest software was used for acquisition and analysis of data.
Mouse tumor model studies
The in vivo antitumor potency of M3, Adv5/dE1A or Adv-TK was tested in the following tumor models. Female athymic BALB/c mice were obtained from the Animal Experimental Center of Slaccas (Shanghai, China). Mice were used when 4-6 weeks of age and were maintained in a laminar-flow cabinet under specific pathogen-free conditions. In the direct intratumoral injection studies performed to measure the antitumor efficacy of virus mutant as a single agent, 2 Â 10 6 HeLa cells were injected subcutaneously in the flanks of mice. When tumors had grown to approximately 6-7 mm, 1 Â 10 8 PFU of Adv-tk, Adv/dE1A or M3 was injected directly into tumors once daily for 5 consecutive days (n ¼ 12 for each group). Mice in the control group were treated with PBS in an identical fashion (n ¼ 12). Tumor sizes were determined twice weekly until mice were killed (tumor volume41000 mm 3 or 140 days after treatment). To obtain evidence of in vivo virus mutant replication and assessment of endogenous chk2 protein levels, a parallel experiment was performed. Mice (n ¼ 2 for each group) were treated under identical experimental conditions. At 40 days after initiation of treatment, mice were killed and primary tumors were collected for in situ hybridization staining for viral fiber mRNA and Western blot analysis. For intravenous injection studies, an orthotopic HepG2 human hepatic carcinoma model was used. First, 2 Â 10 6 HepG2 cells were injected subcutaneously in the flanks of nude mice and allowed to form tumors. When subcutaneous HepG2 tumors had grown to 7-8 mm diameter or 3 weeks after injection of HepG2 cells, the nude mice were killed and tumors were collected and cut into small pieces about 1 mm 3 size each. The tumor pieces were implanted into the livers of nude mice. A left subcostal incision was made under anesthesia using 20% urethane (10 ml/kg). The left lobe of the liver was exposed and the liver capsule mechanically pierced with needle. One piece of tumor was filled into the liver tissue with a forceps, and the abdominal wall was closed with sutures. The animals were maintained in laminar-flow cabinets under specific pathogen-free conditions for about 4 weeks to allow orthotopically placed hepatic tumors to grow. Growth of hepatic tumors was monitored weekly with B-ultrasound.
When hepatic tumor size had reached 3 mm, the animals were divided into four groups (n ¼ 12 for each group) as described previously and injected intravenously with either of the virus mutants at a dose of 2 Â 10 8 PFU for 5 consecutive days. After a 4-day interval, cisplatin at a dose of 0.75 mg/kg/day was injected into the abdominal cavity for 4 consecutive days. Tumor sizes were monitored weekly by B-ultrasound until animals were killed (tumor volume41200 mm 3 or 140 days after treatment). Tumors, lungs, livers and lymph nodes (portal, mesenteric, inguinal and retroperitoneal) were collected at necropsy and processed for histopathological evaluation.
In situ hybridization
In situ hybridization was performed on formalin-fixed, paraffin-embedded tissue sections. Sections were deparaffinized in xylene, rehydrated in a graded series of ethanols and digested with proteinase K at 371C for 30 min. Slides were prehybridized for 30 min at 371C. Hybridization was carried out overnight at 421C with 1 mg/ml biotinylated viral fiber oligonucleotide probe complimentary to the fiber coding region (5 0 -GGA ACT GGC CTT AGT TTT GAC AGC ACA GGT GCC ATT ACA G-3 0 ). After hybridization, the slides were washed three times with 1 Â SSC at 551C. An alkaline phosphatase-conjugated antibiotin antibody (Roche, Basel, Switzerland) was added to bind hybridized probe. The slides were then incubated with NBT/BCIP for 30 min and counterstained once with nuclear fast red.
Statistical analysis
The cell culture data from at least three independent experiments were expressed as means7s.d. and examined by one-way analysis of variance followed by the StudentNewman-Keuls test. Differences at Po0.05 were considered significant. For in vivo data, the cumulative probability of survival was determined by the KaplanMeier method and the significance of differences with the log-rank test. Tumor CR rates and metastasis rates were compared with Fisher's test. All P-values were two-sided and values less than 0.05 were considered significant. SPSS v11.5 software was used for all statistical procedures.
Results
Structure of recombinant adenovirus M3
Recombinant M3 had two artificial modifications compared with wild-type (wt) Adv5 genome (Figure 1a) . First, sequences from Adv5 bases 920-946 (both included), corresponding to the amino-acid sequence D 121 LTCHEAGF 129 of the E1A protein known to be necessary for Rb protein binding, were deleted to generate the mutant adenovirus Adv5/dE1A. This deletion did not produce stop codon, and the Adv5/dE1A could express a mutant E1A protein lacking the CR2 domain essential for efficient pRb binding. Second, a single region in the E3 transcription unit of Adv5/dE1A genome, corresponding to wt-Adv5 bases 28 530-29 360 known to encode E3 6.7K and gp19K protein, was excised and substituted by a fragment of reverse chk2 cDNA (bases 1686-858) with a ClaI restriction site introduced at each end to generate M3 mutant adenovirus. The genomic structure of M3 was verified by ClaI restriction and sequencing. As the native ClaI restriction site (bases 917-922) has been deleted, the genome of M3 contained only two ClaI restriction sites located in the 5 0 -or 3 0 -end of reverse chk2 cDNA. The presence of a 0.8-kb-long band verified the presence of the inserted chk2 cDNA and deletion in the E1A region (Figure 1b) . In this design, reverse chk2 cDNA was fused to the 5 0 portion of the E3 ADP gene and followed the expression pattern of 6.7K and gp19K genes that it replaced. The 6.7K, gp19K and ADP genes can be transcribed as a single transcript, and thus a chimeric mRNA containing reverse sequences of chk2 and sense sequences of ADP was detected by reverse transcriptasepolymerase chain reaction (RT-PCR) in M3-infected A549 lung cancer cells (Figure 1c) . Furthermore, insertion of reverse chk2 cDNA did not change the levels of total ADP transcripts expressed from M3. Both alternatively spliced ADP transcripts from M3 were detected at levels similar to those from Adv5/dE1A (Figure 1d ).
Selective replication of M3 in tumor cells in vitro
We directly measured viral production of M3 in a panel of tumor and normal cells (both non-proliferating and proliferating) by in vitro viral replication assays. Results 
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demonstrated that M3 yielded at least 1000 times increase of viral titers in the two types of cancer cells infected (A549, MDA-MB-231), which was 10-20 times lower but comparable to the replication efficacy of wt-Adv5. In non-proliferating primary normal lung-derived primary human microvascular endothelial cells (Q-MVEC), similar to that of replication-defective Adv-TK, M3 did not yield increased viral titers. In proliferating MVEC (P-MVEC) with a physiologically-inactivated Rb pathway, M3 replication was found operative at a low level, which was several orders of magnitude less than in cancer cells (Figure 2a ). To further confirm preferential replication of M3 in tumor cells, the transcript levels of viral fiber, a late structural viral protein whose expression is dependent on active viral replication, were determined by real-time PCR. Whereas fiber transcripts were nearly undetectable in Adv-TK-infected A549 cells 24 h after infection, in M3-infected A549 cells they were readily detected, at levels similar to those obtained with wt-Adv5 infection. In contrast, fiber transcripts were undetectable in M3-infected Q-MVEC, indicating lack of replication of The CPE potency of M3 was 10-100 times lower than that of wt-Adv5, depending on the cancer cell line tested. In non-proliferating normal cells that would be exposed to high dose of adenovirus after intravenous administration, that is, Q-MVEC and human normal hepatocytes (h NHeps), wt-Adv5 caused complete cell lysis 12 days after infection at a multiplicity of infection (MOI) of 0.1. In contrast, M3 exhibited no detectable CPE on Q-MVEC or h NHeps even at 5000-fold higher MOI under the identical experimental conditions. In P-MVEC with physiologically inactivated G1/S checkpoint, a 5000-fold higher MOI of virus mutant lysed approximately 15% of P-MVEC (Figure 3a) . The results of CPE assays were further confirmed by quantitative methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay as depicted in Figure 3b , which showed that M3 preferentially killed tumor cells in a wide range of viral titers tested.
M3 selectively depleted chk2 protein in cancer but not normal cells Previously, Hawkins et al. had shown that levels of transgene expressed from the E3 6.7K and gp19K region were severely attenuated upon inhibition of DNA replication. The replication-dependent expression could be the results of reduction of viral DNA copies, inhibition of E3 promoter or both. We then determined the transcriptional level of the viral 14.7 K to determine whether E3 promoter was selectively activated in a viral replication-dependent fashion. The level of 14.7 K mRNA from M3 was similar to that of wt-Adv5 in cancer cells (A549, HepG2), indicating that the E3 promoter was highly active in M3-infected cancer cells. In contrast, the 14.7 K mRNA was nearly undetectable in M3-infected Abbreviations: MEVC, microvascular endothelial cells; PBS, phosphate-buffered saline. Tumor cells (MCF-7, A2780, HeLa) and MEVC (non-proliferative or proliferative) were infected with Adv5/dE1A or M3 adenovirus mutants at a MOI of 1 and cultured for another 24 h. PBS was included as a mock control. Cells were then treated as follows: HeLa cells were exposed to irradiation at a dose of 10 Gy, MCF-7 cells and MEVC cells were irradiated at a dose of 6 Gy and A2780 cells were treated with cisplatin at a dose of 20 mM. Then, cells were maintained in complete medium for another 48 h with HeLa, 24 h with MCF-7, 24 h with A2780 or 24 h with MEVC before apoptosis analysis. M3 enhanced DNA damaged-induced apoptosis specifically in tumor cells but not in normal cells (**Po0.001). Figure 5 Therapeutic effect of M3 on subcutaneous human cervical tumor xenografts. (a) The virus mutants were tested for the ability to inhibit in vivo chk2 protein levels. Mice (n ¼ 2 for each group) were treated under identical experimental conditions. At 40 days after initiation of treatment, mice were killed, tumors tissues were collected and chk2 protein expressions were detected by Western blot. Significant decreased chk2 expression was observed in M3-treated tumor compared with PBS-, Adv-TK-and Adv/dE1A-treated ones. (b) Subcutaneous HeLa tumor-bearing mice were divided into four groups (n ¼ 12/group) and directly injected with 1 Â 10 8 PFU of Adv-TK, Adv/dE1A, M3 or PBS (as no treatment control) into tumors once daily for 5 consecutive days. Mice were killed when tumor volume41000 mm 3 or 140 days after treatment. Mice treated with M3 showed significant survival time compared to mice that were not treated or were treated with Adv-TK, Adv/dE1A or PBS. Table 1 ). Antisense chk2 cDNA was thus responsible for the increase in efficacy of killing. The present experiments did not reveal a significant difference in induction of apoptosis between Adv5/dE1A and M3 treatment alone.
M3 mutant adenovirus inhibited tumor growth and metastasis in vivo
To evaluate the benefits of insertion of antisense chk2 cDNA in vivo, we subsequently assessed the antitumor efficacies of M3 versus Adv5/dE1A as a single agent in Balb/C athymic tumor-bearing mice. In agreement with in vitro findings, consequent reduction of chk2 protein also became evident after direct intratumoral injection of M3 but not other virus mutants (Figure 5a ). Direct intratumoral injection of M3 into subcutaneous cervical tumor mice exhibited a survival superior to those of mice undergoing intratumoral injection of Adv-tk (Po0.0001). No survival advantage was gained with M3 when compared with Adv5/dE1A (P ¼ 0.187) (Figure 5b ). We next compared the antitumoral potency of M3 with Adv5/ dE1A in combination with cisplatin in a treatmentresistant tumor model. We chose orthotopic HepG2 human hepatocellular carcinoma model because most adenovirus will accumulate in liver when being administrated intravenously. Active viral replication was detected preferentially in hepatic tumor site by in situ hybridization staining for viral fiber after five doses of intravenous injection of M3 (Figure 6a) . Survival of the groups treated with M3 plus cisplatin was superior to that of groups treated with Adv-TK plus cisplatin (Po0.0001) or Adv5/dE1A plus cisplatin (P ¼ 0.041) (Figure 6b) . A higher number of complete tumor regressions (CR) was achieved following M3 treatment (9/12) than either Adv5/ dE1A (3/12; P ¼ 0.039) or Adv-TK (0/12; Po0.0001) treatment ( Table 2) . None of the mice with CR exhibited tumor recurrence at the end of the study (140 days). All mice (12/12) treated with cisplatin alone died before day 45 after treatment and were found to have metastases within lymph nodes on microscopic examination at the time of killing. For viruses-treated groups, 1/12 with M3, 5/12 with Adv5/dE1A (P ¼ 0.155) and 10/12 with Adv-TK did (P ¼ 0.001) were found to have mesenteric node metastasis ( Table 2) .
Discussion
Oncolytic viruses represent a rapidly evolving novel platform for cancer therapy. Early experience from clinical trials of onyx-015 or likes had shown promising clinical response of these viral agents. Theoretically, it is true that the tumor cells infected by oncolytic adenovirus should die anyway from oncolysis. Unfortunately, the desired oncolysis occur only in cell culture model. Many obstacles in vivo exist to limit the utilities of oncolytic adenovirus to its full potential, which are clearly exemplified by clinical trials with oncolytic adenovirus. 2, [26] [27] [28] [29] Arming oncolytic adenovirus with therapeutic gene proved to be an effective approach to enhance the antitumoral potency and provided best chance for tumor eradication in vivo. Our present study is the first report to arm the E1A mutant with a therapeutic transgene although the delivery of therapeutic transgenes has been Abbreviations: CR, complete tumor regression; PBS, phosphate-buffered saline. Orthotopic HepG2 human hepatic carcinoma model mice were divided into four groups and injected intravenously with either of the virus mutants at a dose of 2 Â 10 8 PFU for 5 consecutive days. After a 4-day interval, cisplatin at a dose of 3 mg/kg/day was injected into the abdominal cavity for 4 consecutive days. Tumor sizes were monitored weekly by B-ultrasound until animals were killed (tumor volume41200 mm 3 or 140 days after treatment). Complete tumor regression (CR) was evaluated. Tumors, lungs, livers and lymph nodes (portal, mesenteric, inguinal and retroperitoneal) were collected at necropsy and processed for histopathological metastasis evaluation. M3 increased CR and decreased metastasis when administrated with chemotherapy in the mice.
made with other less potent oncolytic adenoviruses. 30, 31 Moreover, present data had validated an interesting approach to preferentially target the molecule in tumor cells while sparing normal cells unaffected. This is especially attractive and generally applicable to development of novel antineoplastics by targeting ubiquitous molecules. Of note, delivery of RNAi by dl922-947 has recently been validated to inhibit gene expression. In the same study, however, Carette et al. 31 had not tested therapeutic gene in their system, and the unselective expression of the foreign U6 promoter would make it difficult to limit the gene targeting to tumor cells.
It is well established that targeting chk1 significantly enlarges the therapeutic windows of DNA-damaging agents between cancer and normal cells. Although silencing chk2 demonstrated similar therapeutic effects on tumor cells in many in vitro studies, controversy existed whether chk2 was a real molecule to provide chemoprotection, as no specific chk2 inhibitor was available yet to test antitumoral action of chk2 in vivo. Most recently, Pommier et al. 32 summarized a short list of published chk2 inhibitors, and proposed the possible therapeutic benefit of chk2 gene silencing in the development of the novel therapy against refractory cancer with poor response to conventional anticancer therapies. It is anticipated that small molecule inhibitors will soon be available to test chk2 therapeutic hypotheses. On the other hand, our current approach clearly showed chk2 targeting significantly enhanced the potency of oncolytic adenovirus when in combination with cisplatin, which strongly supported the therapeutic benefits in vivo by targeting chk2.
Metastasis represents the most lethal stage of cancer progression as metastatic cancer responds poorly to conventional therapy, if at all. To give an example of this fact, hepatocellular carcinoma is one of the most common malignant tumors and liver is one of the most involved organs for metastases. Very few patients can be cured owing to the difficulty in controlling the dissemination of the tumor. [33] [34] [35] [36] One of the most significant findings in present study was that cisplatin-refractory hepatic xenograft models responded to a low dose of cisplatin plus intravenous administration of M3. By virtue of combining oncolysis with chk2 targeting, M3 plus cisplatin induced CR in a large portion of tumor mice that were otherwise resistant to cisplatin and disseminated metastases. Whether the findings could be translated into clinical benefits should be determined in future clinical trials, and our present findings presented here are encouraging enough to warrant a clinical evaluation. Although a number of efficacies, safety and manufacturing issues must be addressed for development of oncolytic adenovirus as antitumoral agents, M3 represents an innovative approach that contributes to these efforts. Figure 6 Therapeutic effect of M3 on orthotopic HepG2 human hepatic carcinoma xenografts. (a) Orthotopic HepG2 human hepatic carcinoma mice (n ¼ 2 for each group) were infected with each virus mutant at a dose of 2 Â 10 8 PFU for 5 consecutive days, and then the primary tumor samples were collected. Viral replication was detected preferentially in hepatic tumor site by in situ hybridization staining for viral fiber after five doses of intravenous injection of adenoviruses. Cells that contained replicative virions were stained dark blue (black arrows). Adv-TK-infected ones did not show any virus DNA. (b) Kaplan-Meier survival curves follow intravenous administration of M3 plus DDP to mice. The model mice were divided into four groups as described previously and injected intravenously with either of the virus mutants at a dose of 2 Â 10 8 PFU for 5 consecutive days. After a 4-day interval, cisplatin at a dose of 3 mg/kg/day was injected into the abdominal cavity for 4 consecutive days. Mice were killed when tumor volume41200 mm 3 or 140 days after treatment. Survival of the group treated with M3 plus cisplatin was superior to that of groups treated with Adv-TK plus cisplatin (Po0.0001) or Adv5/dE1A plus cisplatin (P ¼ 0.028). (c) Representative Hematoxylin-Eosin staining of mesenteric lymph node metastases (green arrows) detected in mice treated with Adv-TK plus cisplatin. A mesenteric lymph node in mice treated with M3 plus cisplatin was metastasis-free.
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